AC
Aisling Capital
Private EquityActiveAisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by
94
Investments
41
Exits
$144M
AUM
43.6%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Aisling Capital.
Investment Thesis & Strategy
Aisling Capital invests in various stages of biotech and healthcare companies, seeking to capitalize on the next generation of therapeutics. They look for companies poised to drive innovation in the healthcare sector.
Investment Activity
Deals per year over the last 17 years
1
20051
20062
20072
20080
20091
20101
20112
20120
20130
20141
20150
20160
20170
20180
20190
20201
2021Portfolio Companies
Selected investments from their portfolio of 94 companies
O
Obsidian Therapeutics
Biotech · Series B, 2021
V
Voyager Therapeutics
Biotech · Series A, 2015
M
MyoKardia
Biotech · Series A, 2012
C
Catabasis Pharmaceuticals
Biotech · Series A, 2012
T
TESARO
Biotech · Series A, 2011
R
Radius Health
Biotech · Series A, 2010
E
Epizyme
Biotech · Series A, 2008
E
Esperion Therapeutics
Biotech · Series A, 2008
R
Reata Pharmaceuticals
Biotech · Series A, 2007
A
Achillion Pharmaceuticals
Biotech · Series A, 2007
P
Portola Pharmaceuticals
Biotech · Series A, 2006
A
AMAG Pharmaceuticals
Biotech · Series A, 2005
Frequently Asked Questions
Aisling Capital focuses on Series B, Series C+ stage investments.